

C-1 July E
b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20.

REMARKS

Claims 1-19 and 22-45 were pending in the application. Claims 1-19 and 22-26 have been cancelled, without prejudice, and new claims 46-49 have been added. Accordingly, after the amendments presented herein have been entered, claims 27-49 will remain pending. For the Examiner's convenience all of the pending claims are set forth herein in Appendix A.

Support for the newly added claims can be found throughout the specification and claims as originally filed. Specifically, support for new claims 46, 47, 48 and 49 can be found in claims 27, 28, 37 and 38 as originally filed, respectively. Further support for newly added claims 46-49 can be found at page 11, lines 10-24, and page 8, lines 35-38 of the specification.

No new matter has been added. Any cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite the prosecution of the application. Applicant reserves the right to pursue the claims as originally filed in this or a separate application(s).

Withdrawal From Consideration of Claims 28, 30, 32-36, 38, 40, and 42-45 As Being Directed to a Non-Elected Invention

The Examiner has withdrawn claims 28, 30, 38, 40, and claims 32-36 and 42-45 in so far as they depend from any of claims 28, 30, 38, and 40, as being directed toward an invention that is independent or distinct from the invention originally claimed.

Applicant traverses the withdrawal from consideration of these claims for the following reasons. The polypeptide that the Examiner believes is independent from the invention that was originally claimed (SEQ ID NO:20) is a *splice variant* of claimed polypeptide (SEQ ID NO:5). Both SEQ ID NO:20 and SEQ ID NO:5 are human capsaicin/vanilloid receptor polypeptides and share a high degree of sequence identity. The two polypeptides are identical with the exception of 164 residues that are deleted in the splice variant (see Figure 17 of the instant application for a

sequence alignment) and share the same structural features. Accordingly, the two polypeptides share a common utility which is based upon shared structural and functional features and, thus, have a unity of invention. Moreover, a search of the full length polypeptide would by default also search the splice variant and, thus, no additional searches that would pose undue burden on the Examiner would be necessary. Therefore, SEQ ID NO:20 is not directed toward an invention that is distinct from the invention originally claimed, and Applicant respectfully requests that the claims directed toward SEQ ID NO:20 be considered and examined by the Examiner.

Rejection of Claims 31-36 and 41-45 Under 35 U.S. C. § 112, First Paragraph

The Examiner has rejected claims 31-36 and 41-45, under 35 U.S.C. § 112, first paragraph because, “the specification, *while being enabling for the practice of a method of identifying a ligand which binds to a receptor protein comprising the amino acid sequence presented in SEQ ID NO:5 of the instant specification*, does not reasonably provide enablement for the practice of a binding assay which employs a protein having anything less than the entire amino acid sequence presented in SEQ ID NO:5” (*Emphasis added*). The Examiner is further of the opinion that

[t]he instant specification specifically identifies notable structural features of a protein of the instant invention. It neither provides the identification of the expendable residues in SEQ ID NO:5 nor even a single working example of a functional protein lacking its entire native amino acid sequence.

Applicant traverses this rejection for the following reasons. As indicated in Applicant’s previous reply, the teachings in Applicant’s specification, and the knowledge generally available in the art at the time of filing would allow a skilled artisan to practice the claimed methods using only routine experimentation.

Contrary to the Examiner’s assertions, Applicant has taught in the instant specification which regions of the VR-2 molecules are important for activity and, thus, which regions of the molecule would respond in a binding assay in a manner which is representative of the native protein. Specifically, as taught in the specification (at, for example, page 10, lines 1-35; page 66, lines 30-34; and page 67, lines 1-11), the VR-2 polypeptide contains ankyrin repeats, transmembrane domains, and at least one proline rich domain, all characteristic and necessary for the function of the Capsaicin/Vanilloid family of receptors. Based on these teachings in Applicant’s specification, the skilled artisan would be equipped to use a fragment containing one or more of these functional

domains to identify compounds that bind to a domain and modulate an activity of the Capsaicin/Vanilloid receptor. Compounds identified in such a manner would be of practical value, *e.g.*, they could be used as antagonists of a Capsaicin/Vanilloid receptor. For example, as taught in Applicant's specification a fragment of a VR-2 polypeptide containing the proline rich domain may be used by the skilled artisan to identify compounds capable of binding the proline rich domain and disrupting interactions with SH3 domain-containing proteins that act downstream of the VR-2 receptor in a pain signaling pathway. Such a compound would be expected to inhibit the function of the VR-2 polypeptide by disrupting the VR-2 signaling pathway.

Further, contrary to the Examiner's assertion, Applicant does disclose a working example of a fragment of SEQ ID NO:5. SEQ ID NO:20 is a splice variant of SEQ ID NO:5 that is identical in sequence to SEQ ID NO:5 with the exception of a 134 residue deletion from residue 529-663 (see the sequence alignment presented in Figure 17). Moreover, in Example 5 Applicant discloses specific fragments of SEQ ID NO:5 that were used to generate antibodies against human VR2 (see SEQ ID NOs:13, 14 and 15 at page 70 of the specification).

The Examiner further states that, "Applicant has cited a plurality of patent documents in traversal of this rejection. Applicant is advised that none of the patents cited were available at the time the instant application was filed." Applicant respectfully submits that, although the patents submitted were not *issued* at the time Applicant filed the instant application, the patents were submitted prior to Applicant's filing date and, thus, ***prove that the methods disclosed therein were common and well known to those of ordinary skill in the art at the time of Applicant's filing.***

With respect to the newly added claims 46-49 which are directed to methods of identifying compounds that modulate polypeptides that are 95% identical to the hVR2 molecules, Applicant would like to point the Examiner's attention to Example 14 *Revised Interim Written Description Guidelines Training Materials*. Example 14 provides that a claim directed to variants of a protein having SEQ ID NO:3 "that are at least 95% identical to SEQ ID NO:3 and catalyze the reaction of A→B" with an accompanying specification that discloses a single species falling within the claimed genus, satisfies the requirements of 35 U.S.C. §112, first paragraph for written description. The rationale behind the foregoing conclusion, as presented by the *Written Description Guidelines*, is that "[t]he single species disclosed is representative of the genus because all members have at least 95% structural identity with the reference compound and because of the presence of an assay which Applicant provided for identifying all of the at least 95% identical variants of SEQ ID NO:3 which are capable of the specified catalytic activity." The Guidelines also provide that "[t]he procedures

for making variants of SEQ ID NO:3 are conventional in the art and an assay is described which will identify other proteins having the claimed catalytic activity. Moreover, procedures for making variants of SEQ ID NO:3 which have 95% identity to SEQ ID NO:3 and retain its activity are conventional in the art.”

Similarly, in the present case, the claims are directed to methods which use isolated nucleic acid molecules encoding hVR-2 polypeptides comprising an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NOs:5 and 20, wherein the polypeptide is capable of modulating membrane excitability. Furthermore, Applicant has disclosed in the instant specification assays for identifying all of the at least 95% identical variants of SEQ ID NO:5 and 20 which encode polypeptides capable of modulating membrane excitability (see, for example, the patch-clamp methods taught by the Applicant in Example 4). Modulation of membrane excitability is readily testable by one of skill in the art by the methods described in the instant specification and by methods well-known in the relevant art. Accordingly, it would require only routine experimentation on the part of one of skill in the art to mutate the VR-2 molecules of the invention and test them for the ability to modulate membrane excitability as described in the specification.

Based on the foregoing teachings in Applicant's specification and the knowledge generally available in the art at the time of filing, Applicant respectfully submits that the skilled artisan would be able to make and use the claimed invention using only routine experimentation. Accordingly, Applicant respectfully requests that the Examiner reconsider and withdraw the foregoing rejection.

Rejection of Claim 42 Under 35 U.S. C. § 112, First Paragraph

The Examiner has rejected claim 42 under 35 U.S.C. § 112, first paragraph because, “[i]t was well known in the art prior to the time of the instant application that the yeast two-hybrid system can only employ small soluble proteins as shown in Figure 1 of the Chien *et al.* publication.” The Examiner is further of the opinion that

[o]ne of ordinary skill in the art of molecular biology would immediately recognize that a yeast two-hybrid system which employed all of the amino acid sequence of SEQ ID NO:5 would be inoperative because the presence of the six transmembrane domains within that sequence (Figure 1B of Julius *et al.* Pat. No. 6,335,180). In so far as this claim encompasses a system employing only a soluble portion of the amino acid sequence of SEQ ID NO:5, the instant specification does not disclose a practical utility which is to be realized from the identification of a protein which bind[s] to a portion of that amino acid sequence.

Applicant traverses the forgoing rejection for the following reasons. Contrary to the Examiner's assertions, employing fragments of SEQ ID NO:5 in yeast two hybrid assays would be useful in finding modulators that disrupt pain signaling mechanisms. One of ordinary skill in the art would immediately recognize the potential applications of using fragments of a transmembrane protein in screening assays to identify compounds that are capable of binding to an insoluble transmembrane protein. Identification of a compound that binds to a fragment of a transmembrane protein is useful in the modulation of the activity of the protein. For example, a particularly useful application would be the identification of a compound that is capable of binding to an extracellular region of the transmembrane protein and either blocks natural ligand binding, or itself modulates hVR-2 activity in some other manner. Applicant's specification discloses the presence of proline rich domains in hVR-2 polypeptides. Proline rich domains are known to interact with SH3 domains in proteins that act upstream or downstream of hVR-2 in a pain signaling pathway and, thus, the proline rich domains of VR-2 are useful in screening for modulators that disrupt the pain signaling mechanism. Moreover, Applicant's specification provides a hydrophobicity plot for hVR-2 that an ordinary skilled artisan would be able to use to identify those regions of the protein that are on the cell surface. The use of these portions of the protein would allow for the identification of compounds that themselves modulate the activity of the receptor, or through steric effects, abolish the ability of the receptor to bind to other ligands.

Based on the foregoing teachings in Applicant's specification, and the knowledge generally available to one skilled in the art at the time of filing, it is obvious that the ordinary skilled artisan would realize the applications of using fragments of hVR-2 in a two-hybrid system, and would further be able to make and use the claimed invention using only routine experimentation. Accordingly, Applicant respectfully requests that the Examiner reconsider and withdraw the foregoing rejection.

Rejection of Claims 27, 29, 31-34, 36, 37, 39 41, and 43-45 under
35 U.S.C. 102 (e)

The Examiner has rejected claims 27, 29, 31-34, 36, 37, 39 41, and 43-45, under 35 U.S.C. § 102(e) as being anticipated by Julius *et al.* (United States Patent No. 6,335,180 B1). In particular, the Examiner is of the opinion that "[t]he amino acid sequence presented in SEQ ID

NO:5 of the instant application is identical to the amino acid sequence presented in SEQ ID NO:36 of the Julius *et al.* patent.”

Applicant respectfully traverses the aforementioned rejection for the following reasons. As evidenced by copies of U.S. Application Serial No: 08/915,461, Provisional Application Serial No: 60/072,151 and PCT application Serial No. PCT/US98/17466 (submitted herewith as Appendices B, C, and D, respectively) to which Julius *et al.* claim priority, **SEQ ID NO:36 is not disclosed in any of these applications.** Accordingly, the 35 U.S.C. § 102(e) date that Julius *et al.* are entitled to with respect to SEQ ID NO:36, is **January 22, 1999**, the filing date of the Julius *et al.* patent (6,335,180 B1). Moreover, Julius *et al.* disclose **but do not claim** the amino acid sequence set forth in SEQ ID NO:36.

Applicant submits herewith a declaration under 37 CFR §1.131 which indicates that Applicant has completed the invention as described and claimed in the above-referenced patent application in this country **prior to January 22, 1999**. Accordingly, Applicant respectfully submits that the invention disclosed in the present patent application was reduced to practice by the inventor prior to the effective date of the Julius *et al.* reference. As such, the Julius *et al.* reference is not available as prior art against the present invention under 35 U.S.C. 102§(e), and Applicant respectfully requests that the Examiner reconsider and withdraw this rejection.

Rejection of Claim 35 under 35 U.S.C. 103 (a)

The Examiner has rejected claim 35 under 35 U.S.C. § 103(a) as being unpatentable over Julius *et al.* Specifically, the Examiner believes

[b]ecause the Julius *et al.* patent disclosed the fact that the receptor described therein was naturally expressed in neuronal tissue an artisan would have found it *prima facie* obvious to have expressed that protein recombinantly in a neuronal cell line to obtain a more authentic response by that receptor to a test compound.

Applicant respectfully submits that, in view of the declaration under 37 CFR §1.131 submitted herewith, the aforementioned rejection is rendered moot. Accordingly, Applicant respectfully requests that the Examiner reconsider and withdraw this rejection.

Rejection of Claim 42 under 35 U.S.C. 103 (a)

The Examiner has rejected claim 42 under 35 U.S.C. § 103(a) as being unpatentable over Julius *et al.* in view of Chien *et al.* Specifically, the Examiner believes that

[t]o have incorporated portions of the capsaicin receptor of Julius *et al.* into the yeast two hybrid system of Chien *et al.* to identify proteins with might interact therewith would have been *prima facie* obvious to one of ordinary skill in the art.


Applicant respectfully submits that, in view of the declaration under 37 CFR §1.131 submitted herewith, the Julius *et al.* patent is not available as prior art against the instant application. The Chien *et al.* publication, by itself, is not sufficient to render claim 42 obvious to one of ordinary skill in the art. Accordingly, Applicant respectfully requests that the Examiner reconsider and withdraw this rejection.

SUMMARY

If a telephone conversation with Applicant's attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Maria Laccotripe Zacharakis, Ph.D.

Attorney for Applicant

Limited Recognition Under 37 CFR §10.9(b)

28 State Street
Boston, MA 02109
Telephone: (617) 227-7400
Facsimile: (617) 742-4214

Dated: September 25, 2002

Appendix A

27. A method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5, the method comprising:

- a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

28. A method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20, the method comprising:

- a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20.

29. A method for identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:5, the method comprising:

- a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:5.

30. A method for identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:20, the method comprising:

- a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and

b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:20.

31. A method for identifying a compound which binds to a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:5, the method comprising:

a) contacting a cell expressing the polypeptide with a test compound under conditions suitable binding; and

b) determining whether the test compound binds to said polypeptide, thereby identifying a compound which binds to a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:5.

32. The method of any one of claims 27-31, wherein binding of the test compound to the polypeptide is detected by the use of an assay for a hVR-2 activity.

33. The method of claim 32, wherein said hVR-2 activity is modulation of membrane depolarization.

34. The method of claim 32, wherein said hVR-2 activity is modulation of intracellular calcium levels.

35. The method of any one of claims 27-31, wherein said cell expressing said polypeptide is a neuronal cell.

36. The method of any one of claims 27-31, wherein said compound modulates the activity of said polypeptide.

37. A method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5, the method comprising:

a) contacting a sample comprising the polypeptide with a test compound under conditions suitable for binding; and

b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

38. A method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20, the method comprising:

- a) contacting a sample comprising the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20.

39. A method for identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:5, the method comprising:

- a) contacting a sample comprising the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:5.

40. A method for identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:20, the method comprising:

- a) contacting a sample comprising the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:20.

41. A method for identifying a compound which binds to a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:5, the method comprising:

- a) contacting a sample comprising the polypeptide with a test compound under conditions suitable for binding; and

b) determining whether the test compound binds to said polypeptide, thereby identifying a compound which binds to a polypeptide comprising at least 15 contiguous amino acids of SEQ ID NO:5.

42. The method of any one of claims 27-31 or 37-41, wherein binding of said test compound to said polypeptide is detected by the use of a yeast two-hybrid assay.

43. The method of any one of claims 37-41, wherein binding of said test compound to said polypeptide is detected by the use of a direct binding assay.

44. The method of any one of claims 37-41, wherein binding of said test compound to said polypeptide is detected by the use of a competition binding assay.

45. The method of any one of claims 37-41, wherein said test compound modulates the activity of said polypeptide.

46. A method for identifying a compound which binds to a polypeptide that is 95% identical to the amino acid sequence of SEQ ID NO:5 and is capable of modulating membrane excitability in a cell, the method comprising:

a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and

b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

47. A method for identifying a compound which binds to a polypeptide that is 95% identical to the amino acid sequence of SEQ ID NO:20 and is capable of modulating membrane excitability in a cell, the method comprising:

a) contacting a cell expressing the polypeptide with a test compound under conditions suitable for binding; and

b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20.

48. A method for identifying a compound which binds to a polypeptide that is 95% identical to the amino acid sequence of SEQ ID NO:5 and is capable of modulating membrane excitability in a cell, the method comprising:

- a) contacting the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:5.

49. A method for identifying a compound which binds to a polypeptide that is 95% identical to the amino acid sequence of SEQ ID NO:20 and is capable of modulating membrane excitability in a cell, the method comprising:

- a) contacting the polypeptide with a test compound under conditions suitable for binding; and
- b) determining whether the test compound binds to the polypeptide, thereby identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:20.

Exhibit A

21e11a
Sequencher™ "21e11racefinal"




Exhibit B

21e11a
Sequencher™ "21e11racefinal"

```

flhXc21e11z2 #1 GGCTAGCCTG TCCTGACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGGCCA GGTGGGCTGA GGGTGACCGA GAGACCAGAA
flhXc21e11z1 #1 GGCTAGCCTG TCCTGACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGGCCA GGTGGGCTGA GGGTGACCGA GAGACCAGAA
Genbank N24... >#1> GCTAGCCTG TCCTGACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGNC:A GGTGGGCTGA GGGTGACCGA GAGACCAGAA
Genbank N28... >#1> GCTAGCCTG TCCTGACAGG G:AGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGGC:A GGTGGGCTGA GGGTGACCGN GAGACCAGAA
Genbank N29... >#1> GACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGNC:A GGTGGGCTGA GGGTGACCGA GAGACCAGAA
flhXc21e11i2 >#1> TCCACCGTGC CGGCTGGCCA GGTGGMCTGA GGGTGACCGA NAGACCAGAA

#1 GGCTAGCCTG TCCTGACAGG GGAGAGTTAA GCTCCCGTTC TCCACCGTGC CGGCTGGCCA GGTGGGCTGA GGGTGACCGA GAGACCAGAA
G . P V L T G E S . A P V L H R A G W P G G L R V T E R P E
. . . . . + . + . + .

flhXc21e11z2 #91 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCAGCGCCGG CAGCCCCCTCC CGGCTTCACT
flhXc21e11z1 #91 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCAGCGCCGG CAGCCCCCTCC CGGCTTCACT
Genbank N244... #90 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGNTG TCA
Genbank N280... #90 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCA:CGCCGG CAGCCCCCTCC CGGCTTCACT
Genbank N291... #77 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCA:CGCCGG CAGCCCCCTCC CGGCTTCACT
flhXc21e11i2 #51 CNTGCTTGCT GAAGTTTAGT GTTCAGAGCT GGGGAGGGAG GTTCCGCNGC TCNTCTGCTG TCAGCGCCGG CAGCCCCCTCC NGGCTTCACT
flhXc21e11g2 >#1> CAAAGCT GGGGAGGAAG GTTCCGCNGC TCNTCTGCTG TCAGCGCCGG CAGCCCCCTCC NGGCTTCACT
flhXc21e11g1 >#1> TTCCGCCGN TCNTCTGTTG TCAGCGC:GG CAGCCCNCC NGGCTTCACT
flhX21e11r19... >#1> AGCCCCCTCC CGGCTTCANT
flhX21e11r19... >#1> AGCCCCCTCC CGGCTTCACT
flhXc21e11h1 >#1> AGCCCNCC NGGCTTCANT

#91 CCTGCTTGCT GGAGCTTAGT GCTCAGAGCT GGGGAGGGAG GTTCCGCCGC TCCTCTGCTG TCAGCGCCGG CAGCCCCCTCC CGGCTTCACT
P A C W S L V L R A G E G G S A A P L L S A P A A P P G F T
+ . . . . . + + + . . . + + +

flhXc21e11z2 #181 TCCTCCCGCA GCCCCTGCTA CTGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11z1 #181 TCCTCCCGCA GCCCCTGCTA CTGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
Genbank N28... #180 TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGN GNGGCTCCAG TCAGGCCAAC
Genbank N29... #167 TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11i2 #141 TCCTCCCGCA GCCCNTGCTA CTGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11g2 #68 TCCTCCCGCA GCCCCTGCTA TTGAGAAGC CCC AGCAGCCGCC ACGCCTTGG: CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11g1 #50 TCCTCCCGCA GCCCNTGCTA TTGAGAAGC CCC AGCAGCCGCC ACGCCNTGGC CTCAG:CTG: GGGGCTCCAG TCAGGCCAAC
flhX21e11r19g1 #20 TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhX21e11r19g2 #20 TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11h1 #20 TCCTCCNGCA GCCCTTGNTA CTGAGAAGN :CC AACAGCCGCC ACGCCNCGG: CTCAG:CTG: GGGGNTCCAG TCAGGCCAAC
flhX21e11r21... >#1> CGCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhX21e11b1 >#1> TGANAAGC CCC AGCAGCCNNC ACTCCNTGGC CNNAACCTGC GGGGCTCCAN NNNNNCCAAC
flhXc21e11i1 >#1> TGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11b1 >#1> TGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
flhXc21e11b2 >#1> TGAGAAGC CCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
jthsa103e2b2 >#1> C ACGCGTCCGC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGT GGGGCTCCAG TCAGGCCAAC
jthsa103e2b1 >#1> C ACGCGTCCGC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGT GGGGCTCCAG TCAGGCCAAC
jthsa103e2t2 >#1> C ACGCGTCCGC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGT GGGGCTCCAG TCAGGCCAAC
jthsa103e2t1 >#1> ACGCGTCCGC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGT GGGGCTCCAG TCAGGCCAAC
Genbank AA4... >#1> GCAGCCGC: ACGCCCTGGC CTCAGCCTGC GTGGCTCCAG TCAGGCCAAC
jthsa103e02t... >#1> GCAGCCGCC ACGCCCTGGC CTCAGCCTGT GGGGCTCCAG TCAGGCCAAC
flhX21e11r21... >#1> TGGC CTCAGCNTGC GGGGCTCCAG TCAGGCCAAC
flhX21e11r21... >#1> TCCAG TCAGGCCAAC
flhX21e11r21... >#1> AG TCAGGCCAAC

#181 TCCTCCCGCA GCCCCTGCTA CTGAGAAGCT CCGGGATCCC AGCAGCCGCC ACGCCCTGGC CTCAGCCTGC GGGGCTCCAG TCAGGCCAAC
S S R S P C Y . E A P G S Q Q P P R P G L S L R G S S Q A N
. + . + . + + . . . . . + + . . . + + + + +

```

21e11a
Sequencher™ "21e11racefinal"

```

flhXc21e11z2 #271 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TNCATNTGCA CAAANGTCCT GGCTGGACCG AGCAGCCTNC TNCT:CTAGG
flhXc21e11z1 #271 ACCGACGCGC AGCTGGGAGG AAAACANGAC CCTTGACATC TNCATCTGCA CANANGTCCT GGCTGGACCG AGCAGCCTNC TNCT:CTAGG
Genbank N28... #270 ACCGACGCGC A:NTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
Genbank N29... #257 ACCGACGCGC A:NTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
flhXc21e11i2 #231 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11g2 #158 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11g1 #140 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhX21e11r19... #110 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhX21e11r19... #110 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11h1 #110 ACCNACG:GC A:NTTGGAGN AAGACAGGAC CCTTGACATC TCCATCTGCA CANAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhX21e11r21v2 #87 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTNCTAGG
flhX21e11b1 #70 ACCGACGCGC AGTTGGGNGG ANGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11i1 #70 ACCGACGCGC AGNTGGGAGG AANACAGGAC CCTTGACATC TCCATCTGCN CANAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11b1 #70 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhXc21e11b2 #70 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
jthsa103e2b2 #62 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
jthsa103e2b1 #62 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
jthsa103e2t2 #62 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
jthsa103e2t1 #61 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
Genbank AA45... #50 ACCGACGCGC A:CTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGG:CCG AGCAGCCTCC TCCTCC G
jthsa103e02t1... #50 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCC G
flhX21e11r21a2 #35 ACCGACGNGC AGCT:GGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhX21e11r21a1 #16 ACCGACGCGC AGCT:GGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
flhX21e11r21g2 #13 ACCGACGNGC AGNTGGGAGG AAGACAGGAC CCTTGACNTC TCCATCTGCA CAGAGGTCCT GGNTGGACCG AGCAGCCTCC TCCTCCTAGG
Genbank H20... >#1> GAGAGGTCCT GGCTGGACCA NGCAGCCTCC TCCTCC G
Genbank H50... >#1> AGAGGTCCT GGCTGGACNC :GCAGCCTCC TCCTCC G
Genbank H49... >#1> AGAGGTCCT GGCTGGACAT :GCAGCCTCC TCCTCC G
flhX21e11r20... >#1> G AGCAGCCTCC TCCTCCTAGG
flhX21e11r20... >#1> G AGCAGCCTCC TCCTCCTAGG
flhX21e11r22... >#1> G AGCAGCCTCC TCCTCCTAGG
flhX21e11r22... >#1> G AGCAGCCTCC TCCTCCTAGG
flhX21e11r20... >#1> G AGCAGCCTCC TCCTCCTAGG

```

```

#271 ACCGACGCGC AGCTGGGAGG AAGACAGGAC CCTTGACATC TCCATCTGCA CAGAGGTCCT GGCTGGACCG AGCAGCCTCC TCCTCCTAGG
T D A Q L G G R Q D P . H L H L H R G P G W T E Q P P P P R
+ . . . . + + + + + + + + + + + + + + + + + +

```

21e11a

Sequencher™ "21e11racefinal"

[illegible]

21e11a
Sequencher™ "21e11racefinal"

 jthsa103e2w2 >#1>

TG

#361 ATGACCTCAC CCTCCAGCTC TCCAGTTTTT AGTTGGAGA CATTAGATGG AGGCCAAGAA GATGGCTCTG AGCGGACAG AGGAAAGCTG
M T S P S S S P V F R L E T L D G G Q E D G S E A D R G K L
* + * * .. + + + * + * * * * * + .. * +

Sequencher™ "21e11racefinal"

flhXc21e11z1	#451	GATTTTGGGA	GCGGGCTGNC	TTCNTTGGAG	TCACAGTT	C	ACGGNGANGA	CCGGNAATTC	CCCCC	
Genbank N28...	#450	GATTTTGGGA	GCGGGCTGCC	TCCCATGGNT						
Genbank N29...	#437	GATTTTGGGA	GCGGGCTGCN	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT		
flhXc21e11i2	#411	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGT
flhXc21e11g2	#338	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhXc21e11g1	#320	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r19...	#290	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r19...	#290	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhXc21e11h1	#290	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r21...	#267	GATTTTGGGA	GCGGG							
flhXc21e11b1	#250	GATTTTGGGA	NCGGGCTGCC	TCCCATGGAG	TCACAGTTCC	A				
flhXc21e11i1	#250	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCA
flhXc21e11b1	#250	GATTTTGGGA	GCGGGCTG	C	TCCCATGGAG	TCACAGTTCC	AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAA	TAAGAGTCAA
flhXc21e11b2	#250	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
jthsa103e2b2	#242	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
jthsa103e2b1	#242	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
jthsa103e2t2	#242	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
jthsa103e2t1	#241	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
Genbank AA4...	#230	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT	CTCAGA	TAAGAGTCAA
jthsa103e20t...	#230	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT	CTCAGA	TAAGAGTCAA
flhX21e11r21...	#215	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r21...	#196	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r21...	#193	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
Genbank H20...	#131	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT	CTCAGA	TAAGAGTCAA
Genbank H50...	#130	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT	CTCAGA	TAAGAGTCAA
Genbank H49...	#130	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATT	CTCAGA	TAAGAGTCAA
flhX21e11r20...	#112	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r20...	#112	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r22...	#112	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r22...	#112	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r20...	#112	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11rr13...	#71	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r18v2	#67	GA:TTTGGGA	GCGGGCTG							
flhX21e11r18v1	#67	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCT	
flhX21e11r16g2	#67	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r18g2	#67	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r15g2	#67	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r15g1	#67	GATTTTGGGA	GCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r20a1	#67	GATTTTGGGA	NCGGGCTGCC	TCCCATGGAG	TCACAGTTCC		AGGGCGAGGA	CCGGAAATTC	GCCCCCTCAGA	TAAGAGTCAA
flhX21e11r18a2	#67	GATTTTGGGA								

21e11a

Sequencher™ "21e11racefinal"

蘇州府志

[illegible]

21e11a

Sequencher™ "21e11racefinal"

[illegible]

21e11a

1

個



獨

डा

五



#541 CGAAAGGGAA CAGGTGCCAG TCAGCCGGAT CCAAACCGAT TTGACCGAGA TCGGCTCTTC AATGCGGTCT CCCGGGGTGT CCCCAGGAGT
R K G T G A S Q P D P N R F D R D R L F N A V S R G V P E D
++ + +. + +. + . +. +. . . +. +. +. +. +. +.

21e11a
Sequencher™ "21e11racefinal"

flhXc21e11g2	#518	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGNT	CNA
flhXc21e11g1	#500	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGNT	CCA
flhX21e11r19...	#470	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAAT:C	NCAGAGGG	
flhX21e11r19...	#470	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGG	
flhXc21e11h1	#470	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhXc21e11b1	#430	CTGNTTGGAC	TT						
flhXc21e11b2	#430	CTGGCTGGAC	TTTACAGTA	CCTGAGCCAG	ACCAGCAAGT	ACCTC:CCGA	CTCGGAATAC	ACAGAAGGCT	TCACAAGTAA AACGTGCCTG
jthsa103e2t2	#422	CTGGCTGGAC	TTNCAGAGTA	CCTGAGCAAG	ANCAGCAAGT				
jthsa103e2t1	#421	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGANGGCT	NCACANGTAA GACGTGCCTG
jthsa103e02t...	#410	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r21...	#395	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r21...	#376	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r21...	#373	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
Genbank H20...	#311	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCT:ACC	CTTGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
Genbank H50...	#310	CTGGCTGGAT	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	AC			
Genbank H49...	#310	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTTGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r20...	#292	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCNCC	CTCGGAA		
flhX21e11r20...	#292	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAAT		
flhX21e11r22...	#292	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r22...	#292	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r20...	#292	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r1...	#251	CTGGCTGGAC	TT						
flhX21e11r16...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGA	
flhX21e11r18...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGA	
flhX21e11r15...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGA	
flhX21e11r15...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	NCAGAG	
flhX21e11r20...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r18...	#247	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r17...	#243	CTGGCTGGAC	TTTACAGTA	CCTGAGCAAG	ACCAGCAA				
flhX21e11r17...	#243	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGA	
flhX21e11r17...	#243	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r15...	#243	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r15...	#242	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r18...	#242	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r16...	#241	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r17...	#240	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCT:NC	CTCGGAATAC	ACAGANGGCT	TCACANGTNA AACGTGCCTT
flhX21e11r17...	#240	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
flhX21e11r16...	#239	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	NCNGA	
flhX21e11r16...	#239	CTGGCTGGAC	TTCCAGAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA GACGTGCCTG
Genbank AA7...	#212								

21e11a
Sequencher™ "21e11racefinal"

1	flhX21e11xr9c...	#89	CTGGCTGGAC	TTCACAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGCAA	GACGTGCCTG
2	jthsa103e2x2	#74	CTGGCTGGAC	TTCACAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA	GACGTGCCTG
3	Genbank AI00...	#23	CTGGCTGGAC	TTCACAGTA	CCTGAGCAAG	ACCAGCAAGT	ACCTCACC	CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA	GACGTGCCTG
4	jthsa103e2a1	>#1>						CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA	GACGTGCCTG
5	jthsa103e2a2	>#1>						CTCGGAATAC	ACAGAGGGCT	CCACAGGTAA	GACGTGCCTG

#631 CTGGCTGGAC TTCCAGAGTA CCTGAGCAAG ACCAGCAAAT ACCTCACC GA CTCGGAATAC ACAGAGGGCT CCACAGGTAA GACGTGCCTG
L A G L P E Y L S K T S K Y L T D S E Y T E G S T G K T C L
+ + . + . + + . + . + + . . + .

[illegible]

#721 ATGAAGGCTG TGCTGAACCT TAAGGACGGA GTCAATGCCT GCATTCTGCC ACTGCTGCAG ATCGACAGGG ACTCTGGCAA TCCTCAGCCC
M K A V L N L K D G V N A C I L P L L Q I D R D S G N P Q P
. + . . + . + . + . + . + . + .

21e11a
Sequencher™ "21e11racefinal"

```

jthsa103e02t... #590 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGNC ACAGCGC
Genbank AA7... #392 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATT
Genbank AA7... #369 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGTCT GCACATCGCC ATT
flhX21e11rr19... #368 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
flhX21e11rr19... #368 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
Genbank AI1... #366 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
jthsa103e2w2 #363 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
jthsa103e2x1 #358 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
flhX21e11rr1... #324 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGTC ATTGAGAAGA GGAGTCTGCA GTGTGCGAAG
Genbank AA4... #321 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATT
flhX21e11rr1... #321 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GNGTGTNAAG
flhX21e11rr1... #320 CTGGTAAATG CCCAGTGCAC AGATGACTAT TNCCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
flhX21e11rr1... #319 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
Genbank AA8... #314 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATT
Genbank AA2... #303 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
jthsa103e2w1 #274 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
flhX21e11rr9... #269 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGTC ATTGAGAAGA GGAGTCTGCA GTGTGCGAAG
jthsa103e2x2 #254 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
Genbank AI0... #203 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATT
jthsa103e2a1 #131 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
jthsa103e2a2 #131 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
flhX21e11rr14... #25 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG

#811 CTGGTAAATG CCCAGTGCAC AGATGACTAT TACCGAGGCC ACAGCGCTCT GCACATCGCC ATTGAGAAGA GGAGTCTGCA GTGTGTGAAG
      L V N A Q C T D D Y Y R G H S A L H I A I E K R S L Q C V K
                + + . . + . +

```


21e11a
Sequencher™ "21e11racefinal"

```

flhX21e11r19... #458 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
flhX21e11r19... #458 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
Genbank A11... #456 CTCCTGGTGG AGAATGGGGC CAATG
jthsa103e2w2 #453 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
jthsa103e2x1 #448 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
flhX21e11rr1... #414 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rr1... #411 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT NTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rr1... #410 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rr1... #409 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
Genbank AA2... #393 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT G
jthsa103e2w1 #364 CTCCTGGTGG AGAATGGGGC CAATGTGNAT GCCCGGGCCT GCGGCCGC
flhX21e11rr9... #359 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
jthsa103e2x2 #344 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
jthsa103e2a1 #221 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
jthsa103e2a2 #221 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGC
flhX21e11rr1... #115 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
frhob12c4g1... >#1> GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
frhob012c04s... >#1> GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
frhob012c04s... >#1> GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rha2 >#1> GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11xmv2 >#1> GCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rlv1 >#1> CCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
frhoc12c4h3... >#1> TT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rlv2 >#1> TTCCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11xmv1 >#1> AGAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
flhX21e11rja2 >#1> AGGGA CTTGCTTTTA TTTCGGTGAG
Genbank AA9... >#1> TCGGTGAG
Genbank AA9... >#1> TCGGTGAG

```

```

#901 CTCCTGGTGG AGAATGGGGC CAATGTGCAT GCCCGGGCCT GCGGCCGCTT CTTCAGAAAG GGCCAAGGGA CTTGCTTTTA TTTCGGTGAG
      L L V E N G A N V H A R A C G R F F Q K G Q G T C F Y F G E
              + . + . + + + +

```

21e11a
Sequencher™ "21e11racefinal"

```

#504 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#501 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCNCCAG CCTGCAGGCC
#500 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#499 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#449 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#205 CTACCCCTCT CTTGNCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#51 CNACCCCTCT CTTGNCCGC TTGCACCAAG CAGTGGNATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#51 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#51 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#50 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#48 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#47 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#43 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCT:GAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#40 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#36 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#26 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#9 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
#9 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
>#1> CCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
>#1> CCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
>#1> CTTGGCCGC TTGCNCCAAG CAGNGGGATG TGGTAAGCTA CCTNCTGGAG AACCCACACC AGNCCGCCAG CCTGCAGGCC
>#1> TA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
>#1> TA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC

```

```

#991 CTACCCCTCT CTTGGCCGC TTGCACCAAG CAGTGGGATG TGGTAAGCTA CCTCCTGGAG AACCCACACC AGCCCGCCAG CCTGCAGGCC
      L P L S L A A C T K Q W D V V S Y L L E N P H Q P A S L Q A
      + + + + + + + + + + + + + + + + + + + + + + + + + + + +

```

```

#594 ACTGACTCCC AGGGCAACAC AGTC
#591 ACTGACTCCC AGGGCAACAC NGT
#590 ACTGACTCCC AGGGCAACAC AGT
#589 ACTGACTCCC AGGGCAACAC AGTCC
#539 ACTGACTCCC AGGGCAACAC AGTC
#295 ACTGACTCCC AGGGCAACAC AGTC
#141 ANTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATGTCGGN CAANTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#141 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#141 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#140 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#138 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#137 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#133 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#130 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#126 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATGTCGGA CAACTCAGCT GAGAAC
#116 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#99 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#99 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
#88 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#88 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACA
#81 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAA
#43 ACTGACTCCC AGGGCAACAC AGTC
#43 ACTGACTCCC AGGGCAACAC AGTN

```

```

#1081 ACTGACTCCC AGGGCAACAC AGTCCTGCAT GCCCTAGTGA TGATCTCGGA CAACTCAGCT GAGAACATTG CACTGGTGAC CAGCATGTAT
      T D S Q G N T V L H A L V M I S D N S A E N I A L V T S M Y
      + + + + + + + + + + + + + + + + + + + + + + + + + + + +

```

21e11a
Sequencher™ "21e11racefinal"

frhob12c4g1... #231 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTNCAGG ATCTCACGCC TCTGAAGCTG
frhob012c04s... #231 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
frhob012c04s... #231 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
frhoc12c4h3... #223 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
Genbank AA9... #189 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACG
Genbank AA9... #189 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
jthLa029c10t... >#1> CGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
Genbank W38... >#1> CTC TGCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAANTG

#1171 GATGGGCTCC TCCAAGCTGG GGCCCGCCTC TGCCCTACCG TGCAGCTTGA GGACATCCGC AACCTGCAGG ATCTCACGCC TCTGAAGCTG
D G L L Q A G A R L C P T V Q L E D I R N L Q D L T P L K L
+ *

frhob12c4g1... #321 GCCGCCAAGG AGGGCAAGNT CGANATTTC AGGCACATCC TQCA
frhob012c04s... #321 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTTTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
frhob012c04s... #321 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTTTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
frhoc12c4h3... #313 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTTTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
Genbank AA9... #279 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC T
jthLa029c10t... #67 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTTTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
Genbank W386... #65 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTNTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
Genbank AA3... >#1> TTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG

#1261 GCCGCCAAGG AGGGCAAGAT CGAGATTTTC AGGCACATCC TGCAGCGGGA GTTTTCAGGA CTGAGCCACC TTTCCCGAAA GTTCACCGAG
A A K E G K I E I F R H I L Q R E F S G L S H L S R K F T E
+ + *

frhob012c04s... #411 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTG CTCTGTGGA CAGCTGTGAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
frhob012c04s... #411 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCT:G CTCTGTGGA CAGCTGTGAG GAGAACTCAA TGCTGGAGAT CATTGCCTTT
frhoc12c4h3... #403 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTGG CTCTGTGGA CAGCTGTGAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
jthLa029c10t... #157 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTGG CTCTGTGGA CAGCTGTGAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
Genbank W38... #155 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTGG CTCTGTGGA CAGCTGTGAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
Genbank AA3... #38 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTGG CTCTNTGGA CAGCTGTNAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
frhob12c4c1... >#1> GGCTGTGTCG GGTGTGCTG TATGACNTGG CTCTGTGNA CAGCTGTGAN GAGAACTCAG TGCTGGAGAT CATTGCCTTT
Genbank N24... >#1> GAGAACTCAG TGCTGGAGAT CATTGNCCTTT

#1351 TGGTGTATG GGCCTGTCCG GGTGTGCTG TATGACCTGG CTCTGTGGA CAGCTGTGAG GAGAACTCAG TGCTGGAGAT CATTGCCTTT
W C Y G P V R V S L Y D L A S V D S C E E N S V L E I I A F
+ + + + + + *


frhob012c04s... #501 CATTGCAAGA GCCCGCACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG C
frhob012c04s... #501 CATTGCAAGA ACCCGCACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CAT:CCCAAG
frhoc12c4h3... #493 CATTGCAAGA GCCCGCACCG ACACCGAATG GTCGNTTTGN AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG
jthLa029c10t... #247 CATTGCAAGA GCCCGNACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATNCNCAAG
Genbank W38... #245 CATTGCAAGA GCCCGCACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG
Genbank AA3... #128 CATTGCAAGA GCCCGCACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG
frhob12c4c1... #81 CATTGCAAGA GNC CGCACCG ACACNGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG
Genbank N242... #31 CATTGCAAGA GCCCGNACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG

#1441 CATTGCAAGA GCCCGCACCG ACACCGAATG GTCGNTTTGG AGCCCTGAA CAAACTGCTG CANGCGAAAT GGGATCTGCT CATCCCAAG
H C K S P H R H R M V V L E P L N K L L Q A K W D L L I P K
* + + + + + + *

21e11a
Sequencher™ "21e11racefinal"

frhob012c04s... #591	TTCTTCTTAA ACTTCCTG
frhoc12c4h3... #583	TTCTTCTTAA ACTTCCTG
jthLs029c10t... #337	TTCTNTTAA ACTTC
Gembank W38... #335	TTCTTCTTAA ACTTCCTGTG TAATCTGATC TACATGTTCA TCTTCA
Gembank AA3... #218	TTCTTCTTAA ACTTCCTGTG TAATCTGATC TACATGTTCA TCTTCAACGC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA G
frhob12c4c1... #171	TTCTTCTTAA ACTTCCTGTG TAATCTGATN TACATGTTCA TCTTCACC GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA GCAGGCCCGCC
Gembank N24... #121	TTCTTCTTAA ACTTCCTGTG TAATCTGATN TACATGTTCA TCTTCACC GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA GCAGGCCCGCC
fllHx2le1laal... >#1>	TTAA ACTTCCTGTG TAATCTGATN TACATGTTCA TCTTCACC GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA GCAGGCCCGCC
frhob12c4d1... >#1>	TTAA ACTTCCTGTG TAATCTGATC TACATGTTCA TCTTCACC GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA G : GCCGCC
johb003T24ia... >#1>	GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA G : : GCCGCC
johb003T24ia... >#1>	GC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA G : : GCCGCC

#1531 TTCTTCTTAA ACTTCTGTG TAATCTGATC TACATGTTCA TCTTCAACGC TGTTGCCTAC CATCAGCCTA CCCTGAAGAA GCAGGCCGCC
P F L N F L C N L I Y M F I F T A V A Y H Q P T L K K Q A A
+ + *

	Erhob12c4c1... #261	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TMTACCTCCT	CGTGGGCCAG
	Genbank N24... #211	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTCCT	CGTGGG
	flhX21ella1... #85	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TMTACCTCCT	CGTGGGCCAG
	Erhob12c4e1.a... #85	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTCCT	CGTGGGCCAG
	johb003T24ia0... #43	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTCCT	CGTGGGCCAG
	johb003T24ia0... #43	CCTCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTCCT	CGTGGGCCAG
	flhX21ell1ev2... >#1	TCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTNCT	CGTGGGCCAG
	flhX21ella1e2... >#1	TCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TMTACCTCCT	CGTGGGCCAG
	flhX21ella1e1... >#1	TCACCTGA	AAGCGNAGGT	TGGAAACTCC	ANGCTGNTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TMTACCTCCT	CGTGGNCCAG
	flhX21ell1dv1... >#1	TCACCTGA	AAGCGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TCTACCTCCT	CGTGGGCCAG
	flhX21ell1da1... >#1	TCACCTGA	AAGNGGAGGT	TGGAAACTCC	ATGCTGCTGA	CGGGCCACAT	CCTTATCCTG	CTAGGGGGGA	TMTACCTCCT	CGTGGGCCAG

#1621 CCTCACCTGA AAGCGGAGGT TGGAAACTCC ATGCTGCTGA CGGGCCACAT CTTTATCTCTG CTAGGGGGGA TCTACCTCCT CGTGGGCCAG
P H L K A E V G N S M L L T G H I L I L L G G I Y L L V G Q
+ + + + + + +

	frhob12c4c1...	#351	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	flhX2e11aa1...	#175	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATNT	CGTTCATAGA	CAGCTACTNN	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	frhob12c4e1...	#175	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	johb003T24ia...	#133	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	johb003T24ia...	#133	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	flhX2e11ev2...	#89	CTGTGGTACT	TCTGGCGGNG	CCACNTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCN	TCCTGTTNCA	NGCCCTGCTC
	flhX2e11ea2...	#89	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	flhX2e11ea1...	#89	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	flhX2e11dv1...	#89	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC
	flhX2e11da1...	#89	CTGTGGTACT	TCTGGCGGCG	CCACGTGTTT	ATCTGGATCT	CGTTCATAGA	CAGCTACTTT	GAAATCCTCT	TCCTGTTCCA	GGCCCTGCTC

#1711 CTGTGGTACT TCTGGCGGCG CCACGTGTTT ATCTGGATCT CGTTCATAGA CAGCTACTTT GAAATCCTCT TCCTGTTCCA GGCCCTGCTC
L W Y F W R R H V F I W I S F I D S Y F E I L F L F Q A L L
+ + + ++ + + +

21e11a
Sequencher™ "21e11racefinal"

Achrb21e11 ... #425 GGCCTAAGC CAGATGGCAG CCCGGATGAG CGCTGGTGCT TCAGGGTGA GGAGGTGAAC TGGGCTTCAT GGGAGCAGAC GCTGCCTACG
frhob12c4d1 ... >#1> TCAT GGGAGCAGAC GCTGCCTACG

#2431 GGCCTAAGC CAGATGGCAG CCCGGATGAG CGCTGGTGCT TCAGGGTGA GGAGGTGAAC TGGGCTTCAT GGGAGCAGAC GCTGCCTACG
G T K P D G S P D E R W C F R V E E V N W A S W E Q T L P T

Achrb21e11 ... #515 CTGTGTGAGG ACCCGTCAGG GGCAGGTGTC CCTCGAACTC TCGAGAACC TGTCCTGGCT TCCCCTCCCA AGGAGGATGA GGATGGTGCC
frhob12c4d1 ... #25 CTGTGTGAGG ACCCGTCAGG GGCAGGTGTC CCTCGAACTC TCGAGNACCC TGTCCTGGCT TCCCCTCCCA AGGAGGATGA GGATGGTGCC

#2521 CTGTGTGAGG ACCCGTCAGG GGCAGGTGTC CCTCGAACTC TCGAGAACC TGTCCTGGCT TCCCCTCCCA AGGAGGATGA GGATGGTGCC
L C E D P S G A G V P R T L E N P V L A S P P K E D E D G A
+

Achrb21e11 ... #605 TCTGAGGAAA ACTATGTGCC CGTCCAGCTC CTCCAGTCCA ACTGATGGCC CAGATGCAGC AGGAGGCCAG AGGACAGAGC AGAGGATCTT
frhob12c4d1 ... #115 TCTGAGGAAA ACTATGTGCC CGTCCAGCTC CTCCAGTCCA ACTGATGGCC CAGATGCAGC AGGAGGCCAG AGGACAGAGC ANAGGATCTT

#2611 TCTGAGGAAA ACTATGTGCC CGTCCAGCTC CTCCAGTCCA ACTGATGGCC CAGATGCAGC AGGAGGCCAG AGGACAGAGC AGAGGATCTT
S E E N Y V P V Q L L Q S N . W P R C S R R P E D R A E D L
+

Achrb21e11 ... #695 TCCAACCACA TCTGCTGGCT CTGGGGTCCC AGTGAATTCT GGTGGCAAAT ATATATTTTC ACTAACTCAA AAAAAAAAAA AAAAA
frhob12c4d1 ... #205 TCCAACCACA TCTGCTGGCT CTGGGGTCCC AGTGAATTCT GGTGGCAAAT ATATATTTTC ACTAACTCAA AAAAAAAAAA AAAAAAAAAA

#2701 TCCAACCACA TCTGCTGGCT CTGGGGTCCC AGTGAATTCT GGTGGCAAAT ATATATTTTC ACTAACTCAA AAAAAAAAAA AAAAAAAAAA
S N H I C W L W G P S E F W W Q I Y I F T N S K K K K K K K

frhob12c4d1 ... #295 AAAAAAAAAA AAAAAAAAAA

#2791 AAAAAAAAAA AAAAAAAAAA
K K K K K K



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe Zacharakis is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe Zacharakis ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe Zacharakis' employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe Zacharakis ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: August 5, 2003

Harry I. Moatz

Director of Enrollment and Discipline